Allozymes is applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. The company’s first target application is to transform ingredients manufacturing for industries ranging from pharmaceuticals and cosmetics to food and beverages.
Allozymes says it is capable achieving 10X faster and cheaper enzyme development with 200X higher chance of success and 1,000,000X less reagent consumption.
Founded in 2020 in Singapore, Allozymes is a graduate of the Entrepreneur First program which brings together talented founders and supports them at the earliest stages of company formation. The company’s Co-Founder and CTO Akbar Vahidi invented allozymes’ technology when he was serving as a lead research fellow at the National University of Singapore (NUS). Co-Founder and CEO Peyman Salehian also has a PhD from NUS, as well as extensive experience in transferring technologies from lab to the market.
Subscribe for alerts on new companies featured on Startups.Bio
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® …
ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung …
Alchemab identifies naturally occurring protective antibodies that counter complex diseases, such as cancer and neurodegenerative diseases, by mining the antibody repertoires of individuals who are …
Israel-based Wild Biotech is mining wild animal microbiomes for the discovery of novel human therapeutics, based on the “largest database ever assembled of the microbiome …
MUVON Therapeutics is spin-off from the University of Zurich developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or …
Founded in 2020, Chimerna Therapeutics has developed a platform for generating circular RNA, which overcomes the major limitations of RNA therapeutics, namely stability and abundance. …
